XBiotech
XBIT
34 hedge funds and large institutions have $4.22M invested in XBiotech in 2026 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 9 reducing their positions, and 4 closing their positions.
0.19% less ownership
Funds ownership: 6.5% → 6.32% (-0.19%)
8% less funds holding
Funds holding: 37 → 34 (-3)
29% less capital inflows, than outflows
Capital inflows: $250K | Capital outflows: $351K
33% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 9
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $44K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Allworth Financial
Folsom,
California
|
+$78.4K |
| 2 |
Vanguard Fiduciary Trust
Malvern,
Pennsylvania
|
+$75.2K |
| 3 |
Renaissance Technologies
New York
|
+$58K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$20.9K |
| 5 |
GSA Capital Partners
London,
United Kingdom
|
+$16.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$67.1K |
| 2 |
Morgan Stanley
New York
|
-$53.9K |
| 3 |
Millennium Management
New York
|
-$46.7K |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$45.3K |
| 5 |
Squarepoint
New York
|
-$44.7K |
XBIT Hedge Fund Activity: Q3 2026 in Review
34 of the 8,208 institutional investors tracked by Wall St. Rank reported a position in XBiotech (XBIT) for Q3 2026, worth a combined $4.22M — down 7.6% from $4.56M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of XBIT and 2 opened new positions — a net loss of 2 holders — while 9 trimmed existing stakes and 6 added.
The largest buyer was Allworth Financial, opening a new position worth an estimated $78.4K. The largest seller was Citadel Advisors, exiting entirely with an estimated $67.1K sold.
- 34 institutional investors held XBiotech (XBIT) as of Q3 2026, down from 37 in Q2 2026.
- Funds reported $4.22M of XBiotech stock for Q3 2026, down 7.6% quarter-over-quarter.
- 2 funds opened new XBiotech positions in Q3 2026 and 4 closed out, a net change of -2 holders.
- The largest XBiotech buyer in Q3 2026 was Allworth Financial, an estimated $78.4K added.
- The largest XBiotech seller in Q3 2026 was Citadel Advisors, an estimated $67.1K sold.
Based on aggregated 13F filings for Q3 2026.